We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

28 hedge funds and large institutions have $7.07M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.49% less ownership

Funds ownership: 8.2% → 5.7% (-2.5%)

24% less funds holding

Funds holding: 37 → 28 (-9)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

30% less call options, than puts

Call options by funds: $1.99M | Put options by funds: $2.85M

56% less capital invested

Capital invested by funds: $16M → $7.07M (-$8.88M)

69% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 13

Holders
28
Holders Change
-9
Holders Change %
-24.32%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
8
Closed
13
Calls
$1.99M
Puts
$2.85M
Net Calls
-$864K
Net Calls Change
-$7.43M

Top Buyers

Rank Fund Capital Flow
1
JF
Jump Financial
Illinois
+$510K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$322K
3
Walleye Capital
Walleye Capital
New York
+$272K
4
UBS Group
UBS Group
Switzerland
+$93.8K
5
Vontobel Holding
Vontobel Holding
Switzerland
+$21.1K

Top Sellers

Rank Fund Capital Flow
1
OMC
Old Mission Capital
Illinois
-$1.83M
2
CIC
Chase Investment Counsel
Virginia
-$1.81M
3
Citadel Advisors
Citadel Advisors
Florida
-$907K
4
TRCT
Tower Research Capital (TRC)
New York
-$659K
5
HF
HRT Financial
New York
-$536K
Name Holding Trade Value Shares
Change 		Change in
Stake
GEA
26
Glen Eagle Advisors
New Jersey
$930 – – –
CIC
27
Chase Investment Counsel
Virginia
– -$1.81M -22,285 Closed
HF
28
HRT Financial
New York
– -$536K -6,616 Closed
Jane Street
29
Jane Street
New York
– -$518K -6,381 Closed
UMC
30
United Maritime Capital
New York
– -$243K -3,000 Closed
Qube Research & Technologies (QRT)
31
Qube Research & Technologies (QRT)
United Kingdom
– -$111K -1,368 Closed
RPCONE
32
Retirement Planning Company of New England
Rhode Island
– -$110K -1,366 Closed
SCA
33
Snowden Capital Advisors
New York
– -$22K -275 Closed
BWM
34
BerganKDV Wealth Management
Minnesota
– -$19K -229 Closed
SFM
35
Signet Financial Management
New Jersey
– -$16K -200 Closed
TC
36
Truvestments Capital
Florida
– -$16K -200 Closed
MCM
37
MV Capital Management
Maryland
– -$12K -150 Closed
S
38
SignatureFD
Georgia
– -$4K -50 Closed
TCM
39
Tradewinds Capital Management
Washington
– -$2K -30 Closed
SL
40
Savior LLC
Massachusetts
– +$61 +1 +17%
1
2

BIB Hedge Fund Activity: Q1 2022 in Review

28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2022, worth a combined $7.07M — down 56% from $16M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of BIB and 4 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 6 added.

The largest buyer was Jump Financial, opening a new position worth an estimated $510K. The largest seller was Old Mission Capital, cutting an estimated $1.83M.

  • 28 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2022, down from 37 in Q4 2021.
  • Funds reported $7.07M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2022, down 56% quarter-over-quarter.
  • 4 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2022 and 13 closed out, a net change of -9 holders.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2022 was Jump Financial, an estimated $510K added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2022 was Old Mission Capital, an estimated $1.83M sold.

Based on aggregated 13F filings for Q1 2022.